Home > Healthcare > Analytical Instruments > Molecular Analysis > Molecular Cytogenetics Market

Molecular Cytogenetics Market Size

Report ID: GMI8693
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Molecular Cytogenetics Market Size

Molecular Cytogenetics Market size was valued at around USD 2.5 billion in 2023 and is anticipated to register a CAGR of 10.1% between 2024 and 2032. Molecular cytogenetics is a field of biology that combines molecular biology techniques with cytogenetics, the study of chromosomes and their structure and function. It involves investigating genetic material at the molecular level to analyze chromosomal abnormalities, gene mutations, and variations associated with diseases and genetic disorders.

Molecular Cytogenetics Market

To get key market trends

Download Free Sample

There is a significant increase in the prevalence of genetic disorders and cancer globally, fueled by factors such as aging populations, lifestyle changes, and environmental factors. According to the World Health Organization (WHO), genetic disorders and congenital abnormalities impact roughly 2% to 5% of live births. These conditions lead to approximately 30% of admissions to pediatric hospitals and account for roughly half of all childhood deaths in industrialized countries.

Molecular Cytogenetics Market Report Attributes
Report Attribute	Details
Base Year:	2023
Molecular Cytogenetics Market Size in 2023:	USD 2.5 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	10.1%
2032 Value Projection:	USD 5.9 Billion
Historical Data for:	2021 – 2023
No. of Pages:	278
Tables, Charts & Figures:	458
Segments covered:	Product Type, Technology, Application, End-use, and Region
Growth Drivers:	Growing prevalence of genetic disorders and cancer Technological advancements in molecular cytogenetics Rising adoption of personalized medicine Expanding applications in research and clinical diagnostics
Pitfalls & Challenges:	Stringent regulatory scenario High cost of molecular cytogenetic tests

Learn more about the key segments shaping this market

Download Free Sample

Precision medicine customizes treatments based on patients' genetics, disease traits, and treatment responses. Molecular cytogenetics offers crucial genetic insights, allowing clinicians to identify markers, predict outcomes, and select tailored therapies. This approach enhances treatment effectiveness, minimizes side effects, and improves patient outcomes, fostering the integration of molecular cytogenetics into personalized medicine initiatives.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global molecular cytogenetics industry was valued at around USD 2.5 billion in 2023 and is estimated to reach over USD 5.9 billion by 2032, owing to a significant increase in the prevalence of genetic disorders and cancer globally, fueled by factors such as aging populations, lifestyle changes, and environmental factors.

The comparative genomic hybridization (CGH) segment held a substantial revenue share worth USD 978.3 million in 2023, owing to its ability to detect chromosomal imbalances and copy number variations across the entire genome, with benefits such as high sensitivity, specificity, and resolution.

In 2023, North America held a significant share of 40.8% in the molecular cytogenetics market and is predicted to witness substantial growth through 2032, backed by the advanced healthcare infrastructure, coupled with continuous technological advancements and high healthcare expenditure.

Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioView Ltd., Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina, Inc., MetaSystems, PerkinElmer, Inc., and Sysmex Corporation among others.